Ironwood Pharmaceuticals
IRWD
136 hedge funds and large institutions have $1.54B invested in Ironwood Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 54 increasing their positions, 42 reducing their positions, and 19 closing their positions.
229% more call options, than puts
Call options by funds: $6.18M | Put options by funds: $1.88M
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
29% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 42
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
1% less funds holding
Funds holding: 137 → 136 (-1)
5% less capital invested
Capital invested by funds: $1.62B → $1.54B (-$80.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$48.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.6M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.2M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.86M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$6.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMC
Rubric Capital Management (Connecticut)
Stamford,
Connecticut
|
-$74.4M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$11.6M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$6.98M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$6.12M |
| 5 |
Axa
Paris,
France
|
-$5M |
IRWD Hedge Fund Activity: Q1 2016 in Review
136 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2016, worth a combined $1.54B — down 5% from $1.62B a quarter earlier.
Fund positioning in IRWD was balanced in Q1 2016: 19 funds opened new positions, 19 closed out, 54 added to existing stakes and 42 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $48.7M. The largest seller was Rubric Capital Management (Connecticut), exiting entirely with an estimated $74.4M sold.
- 136 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2016, down from 137 in Q4 2015.
- Funds reported $1.54B of Ironwood Pharmaceuticals stock for Q1 2016, down 5% quarter-over-quarter.
- 19 funds opened new Ironwood Pharmaceuticals positions in Q1 2016 and 19 closed out, a net change of 0 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2016 was Consonance Capital Management, an estimated $48.7M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2016 was Rubric Capital Management (Connecticut), an estimated $74.4M sold.
Based on aggregated 13F filings for Q1 2016.